These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 35017699)

  • 41. Favorable outcomes in the treatment of aggressive posterior retinopathy of prematurity.
    Sahinoglu-Keskek N; Akkoyun I; Torer B
    Eur J Ophthalmol; 2021 Jan; 31(1):179-183. PubMed ID: 31718282
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY.
    Harper CA; Wright LM; Young RC; Read SP; Chang EY
    Retina; 2019 Apr; 39(4):700-705. PubMed ID: 29300248
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab.
    Chen SN; Lian I; Hwang YC; Chen YH; Chang YC; Lee KH; Chuang CC; Wu WC
    Retina; 2015 Apr; 35(4):667-74. PubMed ID: 25462435
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TEN-YEAR EPIDEMIOLOGY OF RETINOPATHY OF PREMATURITY TREATMENT IN TAIWAN.
    Kang EY; Hsu KH; Chu SM; Lien R; Wang NK; Lai CC; Chen KJ; Hwang YS; Lin CM; Wu WC
    Retina; 2020 Sep; 40(9):1804-1811. PubMed ID: 31764611
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity.
    Parchand SM; Agrawal D; Gangwe A; Saraogi T; Agrawal D
    Indian J Ophthalmol; 2021 Aug; 69(8):2164-2170. PubMed ID: 34304202
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of post-treatment recurrence between ranibizumab injection and laser photocoagulation for type 1 retinopathy of prematurity.
    Cao JK; Han T; Tang HY; Zhang S; Wang ZH; Feng ZC; Li QP
    BMC Ophthalmol; 2023 Apr; 23(1):137. PubMed ID: 37016343
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prospective clinical study of two different treatment regimens of combined laser photocoagulation and intravitreal bevacizumab for retinopathy of prematurity: the Indian Twin Cities ROP Study (ITCROPS) database report number 9.
    Laveti V; Balakrishnan D; Rani PK; Mohamed A; Jalali S
    Int Ophthalmol; 2020 Dec; 40(12):3539-3545. PubMed ID: 32776299
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity.
    Hong GJ; Stinnett SS; Freedman SF; Wallace DK; Prakalapakorn SG
    J AAPOS; 2021 Jun; 25(3):177-180. PubMed ID: 33964453
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment.
    Süren E; Özkaya D; Çetinkaya E; Kalaycı M; Yiğit K; Kücük MF; Erol MK
    Int Ophthalmol; 2022 Jun; 42(6):1905-1913. PubMed ID: 35094229
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A rare case of aggressive posterior retinopathy of prematurity presenting with exudative retinal detachment.
    Mittal K; Chawla R; Vukkadala T; Azad SV; Vohra R; Daga J
    J AAPOS; 2021 Feb; 25(1):47-50. PubMed ID: 33144201
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage.
    Nazari H; Modarres M; Parvaresh MM; Ghasemi Falavarjani K
    Graefes Arch Clin Exp Ophthalmol; 2010 Dec; 248(12):1713-8. PubMed ID: 20582706
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity.
    Murakami T; Sugiura Y; Okamoto F; Okamoto Y; Kato A; Hoshi S; Nagafuji M; Miyazono Y; Oshika T
    Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2849-2855. PubMed ID: 33744981
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease.
    Menke MN; Framme C; Nelle M; Berger MR; Sturm V; Wolf S
    BMC Ophthalmol; 2015 Mar; 15():20. PubMed ID: 25886603
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Appropriate dose of intravitreal ranibizumab for ROP: a retrospective study.
    Chen Y; Wang S; Chen S; Chen X; Han L; Zhong Q; Zhang K
    BMC Ophthalmol; 2022 Jun; 22(1):271. PubMed ID: 35729540
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-Vascular Endothelial Growth Factor Preparations in the Treatment of Retinopathy of Prematurity: Balancing Risks and Benefits.
    Chawla D; Darlow BA
    Indian Pediatr; 2016 Nov; 53 Suppl 2():S129-S136. PubMed ID: 27915321
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Complications of retinopathy of prematurity treatment.
    Barnett JM; Hubbard GB
    Curr Opin Ophthalmol; 2021 Sep; 32(5):475-481. PubMed ID: 34231532
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Factors associated with refractive outcome in children treated with bevacizumab for retinopathy of prematurity: the importance of retinal vascularization.
    Bayramoglu SE; Sayin N
    Int Ophthalmol; 2022 Oct; 42(10):3199-3210. PubMed ID: 35579771
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.
    Kim J; Kim SJ; Chang YS; Park WS
    Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity.
    Toy BC; Schachar IH; Tan GS; Moshfeghi DM
    Ophthalmology; 2016 Oct; 123(10):2166-75. PubMed ID: 27506484
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
    Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
    Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.